ElleVet Sciences Welcomes Chief Medical Officer
Dr. Joseph Wakshlag, DVM, PhD, DACVN, DACVSMR, joined ElleVet Sciences on Aug. 1 as chief medical officer.
“Dr. Wakshlag will lead our science driven mission to prove the dramatic benefits of our proprietary hemp CBD product line in a range of medical conditions seen in dogs and cats,” said Dr. Michael Williams, PhD, chairman of ElleVet Sciences. “We welcome his strategic insight and deep knowledge of veterinary medicine, as the foremost expert in hemp CBD research for companion animals.”
Dr. Wakshlag is known in the veterinary medicine community as the first doctor to conduct a pharmacokinetic and safety study in dogs and an efficacy clinical trial using CBD on dogs with osteoarthritis that demonstrated the efficacy of hemp-based CBD. Dr. Wakshlag authored the first peer-reviewed published paper in the use of hemp CBD in dogs, based on this research.
“I am pleased to be joining a company so committed to science and research,” said Dr. Wakshlag. “I look forward to a long and productive relationship as chief medical officer at ElleVet and continuing to explore new areas in CBD research to address areas of unmet need in veterinary medicine.”
In addition to the pharmacokinetic, safety and efficacy clinical study on dogs with osteoarthritis in 2017, Dr. Wakshlag and ElleVet are conducting additional clinical trials to demonstrate efficacy of Ellevet hemp CBD in other important medical conditions. These include seizure, oncology, acute pain, and atopic dermatitis, with further trials planned over the next 12-18 months.
Dr. Wakshlag is also a professor of nutrition and sports medicine at Cornell University School of Veterinary Medicine.